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INTRODUCTION
Acute pancreatitis is a potentially fatal condition that results 
in approximately 100 acute admissions per year for most 
acute hospitals in the United Kingdom.1 Approximately 20% 
of patients will develop pancreatic necrosis as a complication 
of acute pancreatitis with infected pancreatic necrosis subse-
quently occurring in 30% to 70% of this group.2,3 The resultant 
mortality is between 20% and 30%.4–9 In most cases of infected 
pancreatic necrosis, intervention is required.10,11
For the last decade, minimally invasive pancreatic necrosec-
tomy has been the gold standard of management for pancreatic 
necrosis requiring intervention.10,12 More recently, endoscopic 
transluminal drainage and necrosectomy have been devel-
oped and shown to be an effective alternative for appropriate 
patients.12,13 Open necrosectomy is a more invasive treatment 
approach and, overall, its use has declined as it has been con-
firmed to be associated with a higher incidence of morbidity and 
mortality.6,14,15 Current evidence is inconclusive regarding the 
advantages of an endoscopic approach compared to minimally 
invasive surgical interventions in terms of clinical outcomes.16 
The TENSION trial concluded that an endoscopic step-up 
approach was not superior to a surgical step-up approach12; 
however, a smaller trial found that an endoscopic approach 
reduced major complications and increased quality of life.17
Patient-level information and costing systems (PLICS) have 
become mandatory for acute activity in NHS hospitals from 
the 2018/2019 financial year, moving forward from reference 
costs.18 Costings are derived from tracking all resources used 
by an individual patient during their admission and calculating 
the actual costs incurred. This provides several advantages over 
the previous reference system which was based on healthcare 
Objectives: To assess both individual patient and institutional costs as well as outcomes in patients with pancreatic necrosis 
who underwent either endoscopic, minimal access or open pancreatic necrosectomy. These data can be used to evaluate clinical 
effectiveness with a view to informing local healthcare providers.
Background: Intervention for infected pancreatic necrosis is associated with a high morbidity, mortality, and long hospital stays. 
Minimal access surgical step-up approaches have been the gold standard of care; however, endoscopic approaches are now offered 
preferentially.
Methods: All patients undergoing endoscopic (EN), minimal access retroperitoneal (MARPN), and open (OPN) necrosectomy at a 
single institution from April 2015 to March 2017 were included. Patients were selected for intervention based on morphology and 
position of the necrosis and on clinical factors. Patient-level costing systems were used to determine inpatient and outpatient costs.
Results: Eighty-six patients were included: 38 underwent EN, 35 MARPN, and 13 OPN. Preoperative APACHEII was 6 versus 9 
versus 9 (P = 0.017) and CRP 107 versus 204 versus 278 (P = 0.012), respectively. Postoperative stay was 19 days for EN versus 
41 for MARPN versus 42 for OPN (P = 0.007). Complications occurred in 68.4%, 68.6%, and 46.2% (P = 0.298), whereas mortality 
was 10.5%, 22.9%, and 15.4% (P = 0.379), respectively. Mean total cost was £31,364 for EN, £52,770 for MARPN (P = 0.008), and 
£60,346 for OPN. Ward and critical care costs for EN were lower than for MARPN (ward: £9430 vs £14,033, P = 0.024; critical care: 
£5317 vs £16,648, P = 0.056).
Conclusions: EN was at least as safe and effective as MARPN and OPN and was associated with markedly reduced hospital stay 
and cost, although some markers of disease severity were higher in patients undergoing MARPN and OPN. These results support 
EN as the preferred approach to necrosectomy, but hybrid utilization of all available techniques remains integral to optimal outcomes.
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resource group (HRG) averages and cannot be easily linked to 
an individual patient.19 HRGs are groupings of clinically similar 
events or treatments that are judged to use comparable levels 
of healthcare resource.20 Patient-level costing allows for more 
accurate comparisons between different organizations nation-
ally and provides more accurate data for agreeing on local 
pricing for patient care. It is also more accessible for clinicians, 
allowing validation of activities and costs and a potential ave-
nue of improving care pathways.18
Previous cost comparisons of endoscopic necrosectomy and 
a step-up surgical approach have demonstrated a trend toward 
reduced cost for an endoscopic approach.12,17,21 The aim of this 
study was to evaluate any potential cost benefit for a particu-
lar intervention for pancreatic necrosis by performing a clini-




All patients undergoing pancreatic necrosectomy at the Royal 
Liverpool University Hospital from April 1, 2015, to March 31, 
2017, were included and analyzed on an intention to treat basis. 
Patients with admissions extending out of these times were 
excluded from the study. This tight time frame was chosen to 
accommodate whole patient episodes in which procedures were 
undertaken within a negotiated block contract, with a fixed 
budget agreed by NHS commissioners. Patients were prospec-
tively recorded on to an electronic database.
All patients were managed in accordance with current IAP/
APA guidelines.10 Intervention was delayed until 4 weeks post 
onset of acute necrotizing pancreatitis unless the clinical condi-
tion of the patient necessitated earlier drainage or laparotomy. 
Every patient was discussed at the weekly benign multidisci-
plinary team (MDT) meeting, attended by pancreatic surgeons, 
endoscopists, radiologists and specialist nurses. The overall 
management plan and the nature of any required intervention 
was agreed by the MDT. The mode of intervention was decided 
on a patient-by-patient basis, following review of the individu-
al’s condition and the position of the necrosis. However, if the 
clinical condition changed, patients were treated accordingly to 
their emergent situation. Specific indications for intervention 
included clinical suspicion or documented infected necrosis, 
ongoing nonimproving organ failure, ongoing gastric or biliary 




Endoscopic (EN) transluminal drainage was the initial inter-
vention in an endoscopic step-up approach. Under endoscopic 
ultrasound (EUS) guidance the optimum site for stent place-
ment was established. Cyst puncture was performed with a 
19-gauge needle and aspirated fluid was sent for culture. A 
lumen apposing metal stent (LAMS) with enhanced deliv-
ery system (Hot AXIOS; Boston Scientific) or biflanged metal 
stent (Nagi; Taewoong Medical Co. Ltd) was placed into the 
collection. Fluoroscopy was not routinely used for Hot AXIOS 
stent insertion. Necrosectomy was then performed using the 
“flush” method of extracavity lavage using jet pump irrigation 
and suction.22 A cap was placed on the tip of the endoscope 
to aid suction. Instrumentation and debridement of the cavity 
was avoided within the cavity. A radial expansion balloon or 
snares were used to unblock the stent if required. The patient 
underwent weekly scheduled repeat necrosectomy procedures 
until necrosectomy was complete; these were undertaken as an 
outpatient if the patient was sufficiently well. Once imaging 
confirmed the cavity had completely collapsed, the stent was 
removed, preferably within 6 weeks of insertion. Multiple metal 
stents or anchoring plastic stents were used at the discretion of 
the endoscopist.
Minimal Access Retroperitoneal Pancreatic Necrosectomy
Minimal access retroperitoneal pancreatic necrosectomy 
(MARPN) was performed as previously described.6,7 Initial 
percutaneous drainage was performed with a 12-French pigtail 
catheter inserted under CT guidance. In patients with central 
or left-sided collections, the drainage catheter was inserted via 
the left flank between the spleen and splenic flexure. It was 
possible to insert catheters anteriorly or via the right flank in 
patients with right-sided or complex collections. MARPN was 
performed under general anesthetic or sedation. The pigtail 
drain was exchanged for a guidewire under fluoroscopic guid-
ance and the tract dilated up to 30 Fr using serial dilators. A 
sheath was inserted into the tract allowing the passage of an 
operating nephroscope. Necrosis was removed piecemeal under 
direct vision with a minimal necrosectomy on the initial proce-
dure due to immature necrosis and to prevent bleeding. Tissue 
samples were sent to microbiology for culture and sensitivities. 
A 10- or 12-Fr nasogastric tube was sutured inside a 28-Fr chest 
drain and inserted into the cavity allowing postoperative irriga-
tion. Repeat MARPNs were performed every 7–10 days until 
necrosectomy was complete and healthy granulation tissue was 
visualized. A fistulogram was performed to confirm the cavity 
had collapsed. The chest drain was downsized to a nasogastric 
tube and the patient was discharged when sufficiently fit.
Open Pancreatic Necrosectomy
At laparotomy, the necrotic area was exposed by transection 
of the gastrocolic and duodenocolic ligaments or through the 
space of Riolan adjacent to the ligament of Treitz, allowing 
blunt dissection then debridement of necrotic tissue. At least 2 
wide bore drains were placed into the cavity through separate 
incisions and the cavity managed by closed continuous local 
lavage.6,23 Abdominal packing and second look laparotomies 
were not routinely performed.
For all techniques, additional percutaneous drains were 
inserted in to flank or loculated collections when indicated.
Statistical Analysis
Descriptive statistics were performed on patient characteristics 
and outcome measures. A Chi-square test or a Kruskall–Wallis 
test was performed to test for statistical significance at the 5% 
level. Univariate logistic regression and multivariate logistic 
regression modeling including all factors with P <0.1 in univar-
iate analysis were also performed.
Outcomes
Length of stay including any admission in the referring center was 
calculated. Procedure-related adverse events (AEs) included bleed-
ing requiring intervention, visceral perforation, problematic fistu-
lae, and stent-related events. AEs were separated into clinical AEs: 
hospital acquired pneumonia, persistent sepsis, pulmonary embo-
lism, cardiac events, and venous thrombosis and procedural AEs: 
bleeding, perforation, fistulae, stent migration, and stent malfunc-
tion. Additional percutaneous drainage was defined as a radiologi-
cal guided drain placed into an extrapancreatic collection.
Economic Analysis
Individual patient costs were provided by the hospital finance 
department for 2015–2016 and 2016–2017 financial years 
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using PLICS. Individual patient costs for all diagnostic tests, 
treatment, inpatient stay, critical care stay, and outpatients were 
available from the Trust finance department. Endoscopy records 
were also interrogated to provide an accurate cost of any stents 
or disposable equipment used, as this is not currently repre-
sented in the PLICS data.
The drugs/treatment category included drugs, high-cost drugs, 
pharmacy costs, and transfusion services. Staff costs consisted 
of both medical staff and allied health professionals including 
physiotherapists, dieticians, occupational therapists and special-
ist nurses. The Clinical Negligence Scheme for Trusts (CNST) 
contributions were not included in the analysis.
A cost consequence analysis (CCA) was performed due to the 
difficulties in establishing one discrete outcome for the proce-
dure required for cost-effectiveness analysis. A CCA is a practi-
cal method by which cost and outcome data can be structured to 
enable decision makers to improve the decision-making process.
We performed a statistical analysis of the comparative costs 
of EN versus MARPN versus OPN, and a subsequent cost com-
parison analysis of EN versus MARPN. Multiple studies have 
demonstrated that a minimal access approach is to be preferred 
over an open approach,6,13,24 unless there are extenuating factors 
necessitating an open approach; therefore, a separate analysis 
to compare these 2 interventions was performed to help inform 
our practice. Such extenuating circumstances include rapid clin-
ical deterioration, sepsis, requiring organ support, or suspected 
additional intra-abdominal pathology such as visceral perfora-
tion or pancreatitis associated visceral infarction.
RESULTS
Clinical Outcomes
In total, 86 patients were included the analysis: 38 patients 
underwent EN, 35 underwent MARPN, and 13 underwent 
OPN. Patient demographic information is shown in Table  1. 
There were no differences in sex, age, etiology, number of ter-
tiary referrals, time to intervention, or modified CT severity 
score between the 3 groups. There was, however, a significant 
difference in the maximum width of collections (113 vs 147 vs 
106 mm for EN, MARPN, and OPN, respectively, P < 0.001) 
and in the location of necrosis. Of 35, 32 (91.4%) patients 
undergoing MARPN had necrosis in the body or tail, whereas 
34 (89.5%) of 38 patients undergoing EN had necrosis in the 
head or body. Patients undergoing OPN and MARPN had 
higher APACHE II scores (6 vs 9 vs 9, P = 0.017) and higher 
CRP levels than those patients treated by EN (107 vs 204 vs 
278, P = 0.012).
Postoperative outcomes are shown in Table  2. The median 
(IQR) total length of stay was significantly different: 52 (29, 
74) days for EN patients, 74 (55, 102) days for MARPN, and 
63 (53, 79) days for OPN (P = 0.007). The postoperative length 
of stay was lower in the EN group compared to MARPN and 
OPN (19 vs 41 vs 42 days, P < 0.001). In-patient mortality was 
4 (10.5%) for EN, 8 (22.9%) for MARPN, and 2 (15.4%) for 
OPN (P = 0.379). Overall AEs occurred in 26 (68.4%) patients 
undergoing EN, 24 (68.6%) for MARPN, and 6 (46.2%) for 
OPN. Procedural-related AEs were higher in the EN group 
(P = 0.002), whereas clinical AEs were higher in the MARPN 
group (P = 0.046). Confirmed infected necrosis was significantly 
higher for MARPN and OPN [32 (91.4%) and 11 (84.6%) 
versus 14 (36.8%) for the EN group], P < 0.001, but only 14 
patients undergoing EN had samples sent for culture, all of 
whom had positive cultures. The common organisms found on 
culture were Escherichia coli, Enteroccocus species, Klebsiella 
species, and Candida albicans. There was no difference in dif-
ference in microbiota cultured between groups. There was no 
significant difference in the number of patients requiring addi-
tional percutaneous drainage (P = 0.115). The median (IQR) 
number of necrosectomies were 4 (2, 5) for EN, 2 (1, 3) for 
MARPN, and 1 for OPN (P < 0.001).
Table 3 shows specific complications occurring in individual 
groups. There was no significant difference in complications 
between the interventions. The incidence of persistent pancre-
atic fistulae was lower after EN compared to MARPN or OPN; 
however, this did not reach statistical significance (P = 0.104). 
In the endoscopic group, stent-related problems occurred in 16 
(42.1%) patients.
Univariate logistic regression analysis (see Supplemental Table 
1, http://links.lww.com/AOSO/A38) was performed for mortal-
ity. This demonstrated that the factors associated with increased 
mortality in the whole cohort of patients were age [odds ratio 
(OR) 1.042, 95% confidence interval (CI) 1.001–1.086] trans-
fer from another center (OR 9.419, 95% CI 1.176–75.441), 
APACHEII score (OR 1.13, 95% CI 1.048–1.230), preoperative 
ICU stay (OR 6.896, 95% CI 2.121–22.419), and percutane-
ous drainage (OR 4.386, 95% CI 1.400–13.736). Multivariate 
logistic regression models (see Supplemental Table 2, http://
links.lww.com/AOSO/A39) were performed for the outcome of 
AEs. They were not performed for mortality due to the small 
TABLE 1.
Patient Demographics
Characteristics Subgroup EN (N = 38) MARPN (N = 35) OPN (N = 13) Total (N = 86) P
Gender, n (%) Female 12 (31.6%) 12 (34.3%) 6 (46.2%) 30 (34.9%) 0.633
 Male 26 (68.4%) 23 (65.7%) 7 (53.8%) 56 (65.1%)  
Age, median (IQR)  58 (47, 72) 69 (49, 75) 58 (55, 71) 60 (49, 74) 0.532
Etiology of Pancreatitis, n (%) Gallstones 23 (60.5%) 18 (51.4%) 3 (23.1%) 44 (51.2%) 0.124
 ERCP 1 (2.6%) 1 (2.9%) 2 (15.4%) 4 (4.7%)  
 Alcohol 8 (21.1%) 6 (17.1%) 5 (38.5%) 19 (22.1%)  
 Idiopathic 3 (7.9%) 1 (2.9%) 0 (0.0%) 4 (4.7%)  
 Other 2 (5.3%) 4 (11.4%) 1 (7.7%) 7 (8.1%)  
 Unknown 1 (2.6%) 5 (14.3%) 2 (15.4%) 8 (9.3%)  
Transfer from another hospital, n (%) Yes 23 (60.5%) 26 (74.3%) 9 (69.2%) 58 (67.4%) 0.430
Days to intervention, median (IQR)  31 (11, 46) 30 (20, 45) 23 (7, 31) 30 (11, 42) 0.257
CT width (mm) of collection, median (IQR)  113 (87, 147) 147 (130, 178) 106 (75, 155) 134 (102, 160) <0.001
CT severity score, n (%) Moderate 9 (23.7%) 8 (22.9%) 2 (15.4%) 19 (22.1%) 0.882
 Severe 29 (76.3%) 27 (77.1%) 11 (84.6%) 67 (77.9%)  
Day 7 post admission RLUH CRP, median (IQR)  107 (55, 228) 204 (107, 244) 278 (183, 335) 183 (93, 248) 0.012
Preoperative ITU stay, n (%) Yes 5 (13.2%) 9 (25.7%) 6 (46.2%) 20 (23.3%) 0.047
Site, n (%) Head 10 (26.3%) 3 (8.6%) 3 (23.1%) 16 (18.6%) 0.028
 Body 24 (63.2%) 20 (57.1%) 5 (38.5%) 49 (57.0%)  
 Tail 4 (10.5%) 12 (34.3%) 5 (38.5%) 21 (24.4%)  
Total APACHE II score, median (IQR) 6 (2, 9) 9 (5, 12) 9 (6, 16) 7 (4, 11) 0.017
Significant results are indicated in bold.
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number of events. Patients with pancreatitis secondary to alco-
hol (OR 0.191, 95% CI 0.046–0.799) were less likely to suffer 
AEs than those with an etiology of gallstones. A longer length 
ICU stay was also associated with increased AEs (OR 1.112, 
95% CI 1.008–1.227).
Economic Outcomes
Individual patient costs were calculated using PLICS are sum-
marized in Table  4 and Figure  1. The mean overall cost per 
patient was £30,981 for patients treated by EN, £52,357 for 
MARPN, and £60,077 for OPN (P = 0.006). Similarly, the 
ward and intensive care costs were £9430 and £14,033; £9890 
(P = 0.089) and £5317; £16,648 and £24,722 for EN, MARPN, 
and OPN, respectively (P = 0.001).
Table  5 and Figure  2 show a cost comparison of EN and 
MARPN which demonstrates a significantly lower average total 
cost for EN (£30,981) when compared to MARPN (£52,537) 
(P = 0.004). The cost of ward care (£9430 vs £14,033, P = 0.035) 
and medication (£1852 vs £3910, P = 0.006) were also signifi-
cantly lower for patients undergoing EN. The operating room 
costs in the MARPN group were comparable with endoscopy 
costs for patients managed by EN (£4420 and £4135).
DISCUSSION
This study has investigated the actual cost alongside clinical 
outcomes for different approaches for the management of pan-
creatic necrosis in a real-world setting. All patients undergoing 
EN, MARPN, or OPN at a tertiary center over 2 financial years, 
TABLE 2.
Postoperative Descriptive Statistics
Outcomes EN (N = 38) MARPN (N = 35) OPN (N = 13) Total (N = 86) P
Total length of stay (d), median (IQR) 52 (29, 74) 74 (55, 102) 63 (53, 79) 63 (45, 85) 0.007
Length of stay in RLBUHT (d), median (IQR) 28 (17, 50) 55 (39, 81) 48 (36, 58) 42 (26, 64) <0.001
Postoperative length of stay (d), median (IQR) 19 (8, 41) 41 (28, 70) 42 (26, 54) 34 (19, 55) <0.001
In-patient mortality, n (%) 4 (10.5%) 8 (22.9%) 2 (15.4%) 14 (16.3%) 0.379
90-d mortality, n (%) 4 (10.5%) 8 (22.9%) 3 (23.1%) 15 (17.4%) 0.323
AEs, n (%) 26 (68.4%) 24 (68.6%) 6 (46.2%) 56 (65.1%) 0.298
AE (procedure), n (%) 19 (50.0%) 5 (14.3%) 2 (15.4%) 26 (30.2%) 0.002
AE (clinical), n (%) 14 (36.8%) 23 (65.7%) 6 (46.2%) 43 (50.0%) 0.046
Infected necrosis, n (%) 14 (36.8%) 32 (91.4%) 11 (84.6%) 57 (66.3%) <0.001
Total ITU stay (d), median (IQR) 0 (0, 0) 0 (0, 5) 3 (0, 22) 0 (0, 3) 0.003
Percutaneous drainage, n (%) 9 (23.7%) 16 (45.7%) 4 (30.8%) 29 (33.7%) 0.115
No. necrosectomies, median (IQR) 4 (2, 5) 2 (1, 3) 1 (1, 1) 2 (1, 4) <0.001
Significant results are indicated in bold.
TABLE 3.
Adverse Events
Characteristics EN (N = 38) MARPN (N = 35) OPN (N = 13) Total (N = 86) P
Bleeding, n (%) 1 (2.6%) 4 (11.4%) 1 (7.7%) 6 (7.0%) 0.304
Fistula, n (%) 1 (2.6%) 5 (14.3%) 2 (15.4%) 8 (9.3%) 0.104
HAP, n (%) 2 (5.3%) 5 (14.3%) 1 (7.7%) 8 (9.3%) 0.420
Cardiac, n (%) 2 (5.3%) 2 (5.7%) 0 (0.0%) 4 (4.7%) 1.000
Persistent sepsis, n (%) 3 (7.9%) 7 (20.0%) 2 (15.4%) 12 (14.0%) 0.339
PE, n (%) 1 (2.6%) 1 (2.9%) 0 (0.0%) 2 (2.3%) 1.000
PV thrombosis, n (%) 2 (5.3%) 0 (0.0%) 0 (0.0%) 2 (2.3%) 0.636
SMV thrombosis, n (%) 6 (15.8%) 2 (5.7%) 1 (7.7%) 9 (10.5%) 0.404
Readmission, n (%) 10 (26.3%) 11 (31.4%) 3 (23.1%) 24 (27.9%) 0.850
Perforation, n (%) 2 (5.3%) 1 (2.9%) 0 (0.0%) 3 (3.5%) 1.000
TABLE 4.
Summary Table of the Average Cost (£) per Patient for EN, OPN, 
and MARPN
Department EN (£) MARPN (£) OPN (£) P
Wards 9430 14,033 9890 0.089
ITU/critical care 5317 16,648 24,722 0.001
Staff 5358 7648 6501 0.298
Drugs/treatment 1852 3910 6807 0.024
Theaters 784 4420 5369 0.001
Endoscopy 4135 245 0 0.001
Diagnostic tests 2970 3762 5738 0.378
outpatients 1135 1691 1050 0.611
TOTAL 30,981 52,357 60,077 0.006
Significant results are indicated in bold.
HAP, hospital acquired pneumonia; PE, pulmonary embolus; PV, portal vein; SMV, superior  
mesenteric vein.
FIGURE 1. Graph showing average cost (£) per patient for EN, OPN, and 
MARPN.
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within a block UK NHS financial contract period, were included 
in the analysis. The results give an accurate representation of 
current costs for treating this complex cohort of patients with 
long and resource heavy inpatient stays. The most important 
finding is that patients undergoing EN had outcomes equivalent 
to those undergoing MARPN or OPN, with reduced inpatient 
stays and reduced treatment costs. Despite the less severe dis-
ease profile of patients undergoing EN; however, the average 
cost of EN was £30,981, whereas the NHS National Tariff for 
pancreatic necrosectomy for the 2019/2020 financial year was 
only £21,212, substantially less than it costs a center to treat 
the majority of these patients.25,26 Those responsible for com-
missioning and allocating resources for health services should 
ensure that these essential costs are met.
The average cost for managing a patient with MARPN 
was over £20,000 more expensive than for EN. The increased 
cost is largely due to the significantly longer length of stay of 
the MARPN patients on both a surgical ward and ICU. The 
increased length of stay for MARPN of approximately 3 weeks 
is likely to be related to many factors, including being per-
formed in a sicker cohort of patients and the need to prolong 
hospital stay until drain irrigation has been discontinued and 
drain downsized. Contrastingly, our protocol for EN is an initial 
transgastric drainage, followed by flush necrosectomy at 7 days; 
clinically well and suitable patients can then be discharged, 
without the need for irrigation, with EN performed on a weekly 
outpatient basis until the necrotic collection has resolved. It is 
reassuring that there was no increase in readmission following 
EN, suggesting that the protocol is safe. The finding of a reduced 
length of stay for endoscopic necrosectomy is consistent with 
previously published studies.12,17
OPN was associated with higher costs than the less inva-
sive approaches, as OPN was associated with higher ICU costs 
and longer ICU stays. Previously published studies have found 
increased morbidity with OPN compared to minimal access 
techniques.6,7,13,24,27 Bakker et al13 observed a trend toward 
increased ITU stays for OPN, but this did not reach statisti-
cal significance; they also reported an increased inflammatory 
response following open surgical necrosectomy compared to 
EN. This may be partly responsible for the increased ITU stay 
and costs found for OPN. However, the OPN cohort in our 
analysis may have been more physiologically unstable initially, 
as we report higher CRP values and APACHEII scores for the 
OPN compared to the EN patients.
This study is an observational analysis with intervention 
decided by the MDT rather than by randomization. We started 
performing EN shortly before the time frame included in this 
study, so the learning curve period for the technique is included 
in these data. As clinicians became more experienced with the 
technique, it was performed on a wider range of patients, includ-
ing those on ICU and those with less favorable collections. The 
preoperative patient characteristics show that MARPN and OPN 
were performed in patients with higher APACHEII scores, higher 
CRP and associated with more ICU admissions then EN, limiting 
direct comparisons. Any patient who deteriorated was reassessed 
and the plan of intervention adjusted accordingly. Patients wait-
ing for EN (who required a specialist endoscopist) or patients 
waiting for MARPN (who required an interventional radiology 
guidewire/drain placement as part of the procedure), in whom 
appropriate infra-structure was not immediately available and in 
whom it was felt life was in danger, underwent surgical interven-
tion. Judgments of best care are commonplace in tertiary units, 
dealing with inter-regional transfers at high volume.
The site of the pancreatic necrosis has implications for the 
approach chosen; for EN, the collection has to be accessible via 
the transgastric or transduodenal route, whereas collections in 
the tail may be inaccessible. For MARPN, collections have to be 
approached via the flanks, although central or right-sided col-
lections may also be accessible percutaneously in some patients.
Treatment algorithms have not been widely used for pancre-
atic necrosis, given the heterogeneity of the disease and vari-
ations in local expertise. One group is continuing to develop 
an algorithm to define the role of surgical approaches by time 
from onset of pancreatitis and hemodynamic status.28 We feel 
the optimal way to approach pancreatic necrosis is to use a 
treatment algorithm taking into account the location of the 
necrosis and physiological condition of the patient to deter-
mine the management approach. This includes percutaneous 
drains, endoscopic, minimal access, and complex minimal access 
including single-port necrosectomy,29 open necrosectomy or a 
combination of the above. Our work is ongoing.
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